Concepedia

Author

Jennifer A. Low

National Cancer InstituteORCID

Also Known As

J A Low, J. A. Low, J. Low, J.A. Low, Jennifer A Low, Jennifer A. Low, Jennifer A. Low (book editor), Jennifer Low, Jia Qi Low, Low, Jennifer

157

Publications

9.5K

Citations

32

H-Index

81

Concepts

All Affiliations

National Cancer InstituteJohns Hopkins UniversityThe Barbara Ann Karmanos Cancer InstituteCenter for Cancer ResearchUniversity of Colorado Denver
JA

About

Jennifer A. Low is an author at National Cancer Institute specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

14

21

2.7K

2

Health Sciences

4

4

874

3

Language Studies

2

2

24

4

Natural Sciences

1

1

10

5

Biochemistry

1

1

10

Jennifer A. Low

×

42

Publications

8.6K

Citations

28

H-Index

YearCitations

Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

Aleksandar Sekulić, Michael R. Migden, Anthony E. Oro,

New England Journal of Medicine

2012

1.4K

Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma

Daniel D. Von Hoff, Patricia LoRusso, Charles M. Rudin,

New England Journal of Medicine

2009

1.1K

Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449

Charles M. Rudin, Christine L. Hann, John Laterra,

New England Journal of Medicine

2009

1K

<i>Smoothened</i> Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma

Robert L. Yauch, Gerrit J.P. Dijkgraaf, Bruno Alicke,

Science

2009

837

Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

Patricia LoRusso, Charles M. Rudin, Josina C. Reddy,

Clinical Cancer Research

2011

544

Antiangiogenic and Antitumor Effects of Bevacizumab in Patients With Inflammatory and Locally Advanced Breast Cancer

Suparna Wedam, Jennifer A. Low, Sherry X. Yang,

Journal of Clinical Oncology

2006

521

An Oncogenic <i>NTRK</i> Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

Robert C. Doebele, Lara E. Davis, Aria Vaishnavi,

Cancer Discovery

2015

385

Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies

Shivaani Kummar, Robert J. Kinders, Martin Gutierrez,

Journal of Clinical Oncology

2009

324

Inhibition of Poly(ADP-Ribose) Polymerase Enhances Cell Death and Improves Tumor Growth Delay in Irradiated Lung Cancer Models

Jeffrey M. Albert, Carolyn Cao, Kwang Woon Kim,

Clinical Cancer Research

2007

263

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Metastatic and Locally Advanced Breast Cancer

Jennifer A. Low, Suparna Wedam, James J. Lee,

Journal of Clinical Oncology

2005

214

Page 1